Internal Medicine, Medical Oncology · Tampa, FL
NPI
1407098452
Since 2009
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
3 Tampa General Cir
Tampa, FL, 33606
Phone (813) 390-6329
Groups this clinician bills Medicare through
Medicare paid, 2024
$205K
13,116 services
Medicare patients, 2024
252
Average age 69
Drug cost, 2024
$1.2M
538 prescriptions
Company payments, 2025
$0
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Hyung C Suh was code 99233 (hospital e&m - subsequent), 539 times for 51 patients. In total Hyung C Suh billed 13,116 services in 32 codes, and Medicare paid $205K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 539 | 51 | $99.86 | $54K |
| J2562 Injection, plerixafor, 1 mg | Office | 537 | 15 | $9.62 | $5,165 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 508 | 200 | $13.75 | $6,986 |
| 99215 Office E&M - Established | Office | 473 | 174 | $151.94 | $72K |
| 99214 Office E&M - Established | Office | 247 | 117 | $101.20 | $25K |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 69 | 42 | $26.92 | $1,857 |
| 96372 Injection Administration | Office | 52 | 29 | $12.61 | $656 |
| 99223 Hospital E&M - Initial | Facility | 48 | 45 | $142.34 | $6,832 |
| 99232 Hospital E&M - Subsequent | Facility | 34 | 20 | $66.36 | $2,256 |
| 99239 Hospital Discharge Management | Facility | 32 | 31 | $97.09 | $3,107 |
| 38206 Other Organ Systems | Facility | 22 | 11 | $69.82 | $1,536 |
| 38241 Other Organ Systems | Facility | 22 | 22 | $149.82 | $3,296 |
| 99238 Hospital Discharge Management | Facility | 17 | 17 | $68.96 | $1,172 |
| 38221 Other Organ Systems | Office | 17 | 15 | $136.18 | $2,315 |
| 38220 Other Organ Systems | Office | 16 | 14 | $65.70 | $1,051 |
By year: 2022 $250K for 17,211 services; 2023 $245K for 24,726 services; 2024 $205K for 13,116 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36522 General Laboratory | 122 | 13 | $72.96 | $8,901 |
Medicare prescription drug claims, 2024
In 2024, the drug Hyung C Suh prescribed most often to Medicare patients was Levofloxacin, with 72 prescriptions and refills. In total Hyung C Suh wrote 538 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levofloxacin Generic | 72 | 72 | 68 | $703 |
| Valacyclovir Valacyclovir Hcl | 44 | 59 | 19 | $1,475 |
| Plerixafor Generic | 41 | 41 | 38 | $147K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 37 | 41 | 14 | $157 |
| Zarxio Filgrastim-Sndz | 32 | 32 | 26 | $184K |
| Ondansetron Hcl Generic | 26 | 27 | 22 | $154 |
| Pantoprazole Sodium Generic | 25 | 25 | Under 11 | $158 |
| Dexamethasone Generic | 15 | 16 | Under 11 | $970 |
| Rezurock Belumosudil Mesylate | 15 | 15 | Under 11 | $306K |
| Nivestym Filgrastim-Aafi | 13 | 13 | 12 | $67K |
| Atorvastatin Calcium Generic | 12 | 14 | Under 11 | $39.74 |
| Xospata Gilteritinib Fumarate | 12 | 12 | Under 11 | $334K |
Brand drugs: - claims; generic drugs: 434 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Hyung C Suh $0 (- in general payments such as food, travel and fees) from 3 companies.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.